Roxanne Taylor was named chief marketing and communications officer at Memorial Sloan Kettering Cancer Center.
Contrary to declarations by Moffitt Cancer Center, Thomas Sellers, the institution's ousted director, was not involved in the Thousand Talents program sponsored by the People's Republic of China, said a Florida attorney who represents Sellers in preparing a lawsuit against the cancer center.
On Jan. 17, Moffitt Cancer Center officials delivered the final report of the institution's internal investigation to the Florida legislature, alleging that top leaders and researchers at the cancer center had opened personal bank accounts in China and received unreported personal payments and other research support.
What's happening at H. Lee Moffitt Cancer Center?
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
FDA has accepted a supplemental New Drug Application for Rubraca (rucaparib) and granted priority review status to the application with a Prescription Drug User Fee Act date of May 15.
FDA has accepted supplemental Biologics License Application for Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations.
Concerto HealthAI, a health IT company that develops AI technology for precision oncology, has:
Roche and Illumina have entered into a 15-year non-exclusive partnership with to broaden the adoption of distributable next-generation sequencing based testing in oncology.
Qiagen and Amgen are collaborating to develop tissue-based companion diagnostics for Amgen's investigational cancer treatment AMG 510 to identify patients with cancers that have the KRAS G12C mutation.
